nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—ABCB1—ovarian cancer	0.281	1	CbGaD
Nefazodone—CYP3A7—Paclitaxel—ovarian cancer	0.0452	0.0991	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0452	0.0991	CbGbCtD
Nefazodone—ABCB1—Topotecan—ovarian cancer	0.0446	0.0977	CbGbCtD
Nefazodone—CYP3A5—Paclitaxel—ovarian cancer	0.0339	0.0743	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0327	0.0716	CbGbCtD
Nefazodone—CYP3A7—Docetaxel—ovarian cancer	0.0327	0.0716	CbGbCtD
Nefazodone—ABCB1—Vinorelbine—ovarian cancer	0.0314	0.0688	CbGbCtD
Nefazodone—CYP2D6—Vinorelbine—ovarian cancer	0.0296	0.0649	CbGbCtD
Nefazodone—CYP3A4—Topotecan—ovarian cancer	0.0267	0.0585	CbGbCtD
Nefazodone—CYP3A5—Docetaxel—ovarian cancer	0.0245	0.0537	CbGbCtD
Nefazodone—ABCB1—Paclitaxel—ovarian cancer	0.0221	0.0484	CbGbCtD
Nefazodone—CYP3A4—Vinorelbine—ovarian cancer	0.0188	0.0412	CbGbCtD
Nefazodone—ABCB1—Docetaxel—ovarian cancer	0.016	0.035	CbGbCtD
Nefazodone—CYP3A4—Paclitaxel—ovarian cancer	0.0132	0.029	CbGbCtD
Nefazodone—ABCB1—Doxorubicin—ovarian cancer	0.0119	0.0261	CbGbCtD
Nefazodone—CYP2D6—Doxorubicin—ovarian cancer	0.0112	0.0246	CbGbCtD
Nefazodone—CYP3A4—Docetaxel—ovarian cancer	0.00956	0.0209	CbGbCtD
Nefazodone—CYP3A4—Doxorubicin—ovarian cancer	0.00712	0.0156	CbGbCtD
Nefazodone—HTR2A—vein—ovarian cancer	0.0012	0.139	CbGeAlD
Nefazodone—SLC6A2—decidua—ovarian cancer	0.000292	0.0336	CbGeAlD
Nefazodone—ADRA1A—epithelium—ovarian cancer	0.000287	0.0331	CbGeAlD
Nefazodone—ADRA2A—myometrium—ovarian cancer	0.000278	0.0321	CbGeAlD
Nefazodone—HTR2C—female reproductive system—ovarian cancer	0.000275	0.0317	CbGeAlD
Nefazodone—SLC6A4—female reproductive system—ovarian cancer	0.000261	0.03	CbGeAlD
Nefazodone—SLC6A2—gonad—ovarian cancer	0.000257	0.0296	CbGeAlD
Nefazodone—SLC6A3—testis—ovarian cancer	0.00023	0.0265	CbGeAlD
Nefazodone—SLC6A2—female reproductive system—ovarian cancer	0.00023	0.0265	CbGeAlD
Nefazodone—HTR2A—embryo—ovarian cancer	0.000228	0.0262	CbGeAlD
Nefazodone—CYP3A5—uterine cervix—ovarian cancer	0.000227	0.0262	CbGeAlD
Nefazodone—ADRA2A—uterine cervix—ovarian cancer	0.000217	0.025	CbGeAlD
Nefazodone—ADRA2A—decidua—ovarian cancer	0.000206	0.0238	CbGeAlD
Nefazodone—ADRA2A—endometrium—ovarian cancer	0.000196	0.0226	CbGeAlD
Nefazodone—HTR2A—epithelium—ovarian cancer	0.000186	0.0214	CbGeAlD
Nefazodone—SLC6A2—testis—ovarian cancer	0.000185	0.0213	CbGeAlD
Nefazodone—ADRA2A—gonad—ovarian cancer	0.000182	0.0209	CbGeAlD
Nefazodone—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000181	0.000768	CcSEcCtD
Nefazodone—ADRA2A—uterus—ovarian cancer	0.000181	0.0208	CbGeAlD
Nefazodone—Vomiting—Vinorelbine—ovarian cancer	0.000181	0.000765	CcSEcCtD
Nefazodone—Dysuria—Epirubicin—ovarian cancer	0.00018	0.00076	CcSEcCtD
Nefazodone—Rash—Vinorelbine—ovarian cancer	0.000179	0.000758	CcSEcCtD
Nefazodone—Dermatitis—Vinorelbine—ovarian cancer	0.000179	0.000757	CcSEcCtD
Nefazodone—Abdominal distension—Doxorubicin—ovarian cancer	0.000179	0.000757	CcSEcCtD
Nefazodone—Hypotension—Paclitaxel—ovarian cancer	0.000178	0.000756	CcSEcCtD
Nefazodone—Headache—Vinorelbine—ovarian cancer	0.000178	0.000753	CcSEcCtD
Nefazodone—Syncope—Docetaxel—ovarian cancer	0.000178	0.000753	CcSEcCtD
Nefazodone—Asthma—Doxorubicin—ovarian cancer	0.000178	0.000752	CcSEcCtD
Nefazodone—Dysphagia—Doxorubicin—ovarian cancer	0.000178	0.000752	CcSEcCtD
Nefazodone—Influenza—Doxorubicin—ovarian cancer	0.000178	0.000752	CcSEcCtD
Nefazodone—Leukopenia—Docetaxel—ovarian cancer	0.000178	0.000752	CcSEcCtD
Nefazodone—Pollakiuria—Epirubicin—ovarian cancer	0.000177	0.000751	CcSEcCtD
Nefazodone—Palpitations—Docetaxel—ovarian cancer	0.000175	0.000742	CcSEcCtD
Nefazodone—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000175	0.000742	CcSEcCtD
Nefazodone—Weight increased—Epirubicin—ovarian cancer	0.000175	0.00074	CcSEcCtD
Nefazodone—Loss of consciousness—Docetaxel—ovarian cancer	0.000174	0.000738	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000174	0.000737	CcSEcCtD
Nefazodone—Weight decreased—Epirubicin—ovarian cancer	0.000174	0.000736	CcSEcCtD
Nefazodone—Cough—Docetaxel—ovarian cancer	0.000173	0.000733	CcSEcCtD
Nefazodone—Angina pectoris—Doxorubicin—ovarian cancer	0.000173	0.000733	CcSEcCtD
Nefazodone—Insomnia—Paclitaxel—ovarian cancer	0.000173	0.000732	CcSEcCtD
Nefazodone—Pneumonia—Epirubicin—ovarian cancer	0.000172	0.000729	CcSEcCtD
Nefazodone—Convulsion—Docetaxel—ovarian cancer	0.000172	0.000728	CcSEcCtD
Nefazodone—Paraesthesia—Paclitaxel—ovarian cancer	0.000171	0.000726	CcSEcCtD
Nefazodone—Hypertension—Docetaxel—ovarian cancer	0.000171	0.000725	CcSEcCtD
Nefazodone—Bronchitis—Doxorubicin—ovarian cancer	0.000171	0.000724	CcSEcCtD
Nefazodone—Dyspnoea—Paclitaxel—ovarian cancer	0.00017	0.000721	CcSEcCtD
Nefazodone—Somnolence—Paclitaxel—ovarian cancer	0.00017	0.000719	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.00017	0.000719	CcSEcCtD
Nefazodone—Myalgia—Docetaxel—ovarian cancer	0.000169	0.000715	CcSEcCtD
Nefazodone—Arthralgia—Docetaxel—ovarian cancer	0.000169	0.000715	CcSEcCtD
Nefazodone—Chest pain—Docetaxel—ovarian cancer	0.000169	0.000715	CcSEcCtD
Nefazodone—Nausea—Vinorelbine—ovarian cancer	0.000169	0.000714	CcSEcCtD
Nefazodone—Dyspepsia—Paclitaxel—ovarian cancer	0.000168	0.000712	CcSEcCtD
Nefazodone—Stomatitis—Epirubicin—ovarian cancer	0.000167	0.000707	CcSEcCtD
Nefazodone—Urinary tract infection—Epirubicin—ovarian cancer	0.000166	0.000705	CcSEcCtD
Nefazodone—Conjunctivitis—Epirubicin—ovarian cancer	0.000166	0.000705	CcSEcCtD
Nefazodone—Dysuria—Doxorubicin—ovarian cancer	0.000166	0.000704	CcSEcCtD
Nefazodone—Decreased appetite—Paclitaxel—ovarian cancer	0.000166	0.000703	CcSEcCtD
Nefazodone—Dry mouth—Docetaxel—ovarian cancer	0.000165	0.000699	CcSEcCtD
Nefazodone—Sweating—Epirubicin—ovarian cancer	0.000164	0.000695	CcSEcCtD
Nefazodone—Pollakiuria—Doxorubicin—ovarian cancer	0.000164	0.000695	CcSEcCtD
Nefazodone—Constipation—Paclitaxel—ovarian cancer	0.000163	0.000692	CcSEcCtD
Nefazodone—Pain—Paclitaxel—ovarian cancer	0.000163	0.000692	CcSEcCtD
Nefazodone—Haematuria—Epirubicin—ovarian cancer	0.000163	0.000691	CcSEcCtD
Nefazodone—Confusional state—Docetaxel—ovarian cancer	0.000163	0.000691	CcSEcCtD
Nefazodone—ADRA2A—female reproductive system—ovarian cancer	0.000162	0.0187	CbGeAlD
Nefazodone—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000162	0.000687	CcSEcCtD
Nefazodone—Anaphylactic shock—Docetaxel—ovarian cancer	0.000162	0.000686	CcSEcCtD
Nefazodone—Oedema—Docetaxel—ovarian cancer	0.000162	0.000686	CcSEcCtD
Nefazodone—Weight increased—Doxorubicin—ovarian cancer	0.000162	0.000685	CcSEcCtD
Nefazodone—Epistaxis—Epirubicin—ovarian cancer	0.000161	0.000684	CcSEcCtD
Nefazodone—Infection—Docetaxel—ovarian cancer	0.000161	0.000681	CcSEcCtD
Nefazodone—Weight decreased—Doxorubicin—ovarian cancer	0.000161	0.000681	CcSEcCtD
Nefazodone—Sinusitis—Epirubicin—ovarian cancer	0.000161	0.00068	CcSEcCtD
Nefazodone—Pneumonia—Doxorubicin—ovarian cancer	0.000159	0.000675	CcSEcCtD
Nefazodone—Shock—Docetaxel—ovarian cancer	0.000159	0.000674	CcSEcCtD
Nefazodone—Thrombocytopenia—Docetaxel—ovarian cancer	0.000158	0.000671	CcSEcCtD
Nefazodone—Tachycardia—Docetaxel—ovarian cancer	0.000158	0.000669	CcSEcCtD
Nefazodone—Feeling abnormal—Paclitaxel—ovarian cancer	0.000157	0.000667	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000157	0.000665	CcSEcCtD
Nefazodone—Bradycardia—Epirubicin—ovarian cancer	0.000156	0.000663	CcSEcCtD
Nefazodone—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000156	0.000661	CcSEcCtD
Nefazodone—ABCB1—myometrium—ovarian cancer	0.000155	0.0179	CbGeAlD
Nefazodone—CYP3A5—female gonad—ovarian cancer	0.000155	0.0178	CbGeAlD
Nefazodone—HTR2A—gonad—ovarian cancer	0.000155	0.0178	CbGeAlD
Nefazodone—Haemoglobin—Epirubicin—ovarian cancer	0.000154	0.000654	CcSEcCtD
Nefazodone—Stomatitis—Doxorubicin—ovarian cancer	0.000154	0.000654	CcSEcCtD
Nefazodone—Anorexia—Docetaxel—ovarian cancer	0.000154	0.000653	CcSEcCtD
Nefazodone—Rhinitis—Epirubicin—ovarian cancer	0.000154	0.000653	CcSEcCtD
Nefazodone—CYP3A5—vagina—ovarian cancer	0.000154	0.0177	CbGeAlD
Nefazodone—Conjunctivitis—Doxorubicin—ovarian cancer	0.000154	0.000652	CcSEcCtD
Nefazodone—Urinary tract infection—Doxorubicin—ovarian cancer	0.000154	0.000652	CcSEcCtD
Nefazodone—Hepatitis—Epirubicin—ovarian cancer	0.000154	0.000651	CcSEcCtD
Nefazodone—Haemorrhage—Epirubicin—ovarian cancer	0.000154	0.000651	CcSEcCtD
Nefazodone—Hypoaesthesia—Epirubicin—ovarian cancer	0.000153	0.000648	CcSEcCtD
Nefazodone—Pharyngitis—Epirubicin—ovarian cancer	0.000153	0.000646	CcSEcCtD
Nefazodone—Sweating—Doxorubicin—ovarian cancer	0.000152	0.000643	CcSEcCtD
Nefazodone—Urticaria—Paclitaxel—ovarian cancer	0.000152	0.000643	CcSEcCtD
Nefazodone—Oedema peripheral—Epirubicin—ovarian cancer	0.000151	0.000641	CcSEcCtD
Nefazodone—Hypotension—Docetaxel—ovarian cancer	0.000151	0.000641	CcSEcCtD
Nefazodone—Haematuria—Doxorubicin—ovarian cancer	0.000151	0.00064	CcSEcCtD
Nefazodone—Body temperature increased—Paclitaxel—ovarian cancer	0.000151	0.000639	CcSEcCtD
Nefazodone—Abdominal pain—Paclitaxel—ovarian cancer	0.000151	0.000639	CcSEcCtD
Nefazodone—Epistaxis—Doxorubicin—ovarian cancer	0.000149	0.000633	CcSEcCtD
Nefazodone—ABCB1—embryo—ovarian cancer	0.000149	0.0172	CbGeAlD
Nefazodone—Sinusitis—Doxorubicin—ovarian cancer	0.000149	0.000629	CcSEcCtD
Nefazodone—Visual impairment—Epirubicin—ovarian cancer	0.000148	0.000627	CcSEcCtD
Nefazodone—ADRA2A—female gonad—ovarian cancer	0.000148	0.017	CbGeAlD
Nefazodone—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000147	0.000625	CcSEcCtD
Nefazodone—ADRA2A—vagina—ovarian cancer	0.000147	0.0169	CbGeAlD
Nefazodone—Insomnia—Docetaxel—ovarian cancer	0.000146	0.00062	CcSEcCtD
Nefazodone—Paraesthesia—Docetaxel—ovarian cancer	0.000145	0.000616	CcSEcCtD
Nefazodone—Erythema multiforme—Epirubicin—ovarian cancer	0.000145	0.000615	CcSEcCtD
Nefazodone—Bradycardia—Doxorubicin—ovarian cancer	0.000145	0.000613	CcSEcCtD
Nefazodone—Dyspnoea—Docetaxel—ovarian cancer	0.000144	0.000611	CcSEcCtD
Nefazodone—Somnolence—Docetaxel—ovarian cancer	0.000144	0.000609	CcSEcCtD
Nefazodone—Tinnitus—Epirubicin—ovarian cancer	0.000143	0.000607	CcSEcCtD
Nefazodone—Haemoglobin—Doxorubicin—ovarian cancer	0.000143	0.000605	CcSEcCtD
Nefazodone—Flushing—Epirubicin—ovarian cancer	0.000143	0.000604	CcSEcCtD
Nefazodone—Rhinitis—Doxorubicin—ovarian cancer	0.000143	0.000604	CcSEcCtD
Nefazodone—Dyspepsia—Docetaxel—ovarian cancer	0.000142	0.000603	CcSEcCtD
Nefazodone—Hepatitis—Doxorubicin—ovarian cancer	0.000142	0.000602	CcSEcCtD
Nefazodone—Haemorrhage—Doxorubicin—ovarian cancer	0.000142	0.000602	CcSEcCtD
Nefazodone—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000141	0.000599	CcSEcCtD
Nefazodone—Pharyngitis—Doxorubicin—ovarian cancer	0.000141	0.000598	CcSEcCtD
Nefazodone—Decreased appetite—Docetaxel—ovarian cancer	0.000141	0.000596	CcSEcCtD
Nefazodone—Hypersensitivity—Paclitaxel—ovarian cancer	0.000141	0.000596	CcSEcCtD
Nefazodone—Oedema peripheral—Doxorubicin—ovarian cancer	0.00014	0.000593	CcSEcCtD
Nefazodone—Pain—Docetaxel—ovarian cancer	0.000138	0.000586	CcSEcCtD
Nefazodone—Constipation—Docetaxel—ovarian cancer	0.000138	0.000586	CcSEcCtD
Nefazodone—HTR2A—female reproductive system—ovarian cancer	0.000138	0.0159	CbGeAlD
Nefazodone—Chills—Epirubicin—ovarian cancer	0.000138	0.000584	CcSEcCtD
Nefazodone—Visual impairment—Doxorubicin—ovarian cancer	0.000137	0.00058	CcSEcCtD
Nefazodone—Asthenia—Paclitaxel—ovarian cancer	0.000137	0.00058	CcSEcCtD
Nefazodone—Alopecia—Epirubicin—ovarian cancer	0.000136	0.000575	CcSEcCtD
Nefazodone—Pruritus—Paclitaxel—ovarian cancer	0.000135	0.000572	CcSEcCtD
Nefazodone—Erythema multiforme—Doxorubicin—ovarian cancer	0.000134	0.000569	CcSEcCtD
Nefazodone—SLC6A2—lymph node—ovarian cancer	0.000134	0.0155	CbGeAlD
Nefazodone—Feeling abnormal—Docetaxel—ovarian cancer	0.000133	0.000565	CcSEcCtD
Nefazodone—Tinnitus—Doxorubicin—ovarian cancer	0.000133	0.000561	CcSEcCtD
Nefazodone—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000132	0.000561	CcSEcCtD
Nefazodone—Flushing—Doxorubicin—ovarian cancer	0.000132	0.000559	CcSEcCtD
Nefazodone—Flatulence—Epirubicin—ovarian cancer	0.000132	0.000558	CcSEcCtD
Nefazodone—Dysgeusia—Epirubicin—ovarian cancer	0.000131	0.000555	CcSEcCtD
Nefazodone—ADRA2A—testis—ovarian cancer	0.000131	0.0151	CbGeAlD
Nefazodone—Diarrhoea—Paclitaxel—ovarian cancer	0.000131	0.000553	CcSEcCtD
Nefazodone—Back pain—Epirubicin—ovarian cancer	0.000129	0.000548	CcSEcCtD
Nefazodone—Muscle spasms—Epirubicin—ovarian cancer	0.000129	0.000545	CcSEcCtD
Nefazodone—Abdominal pain—Docetaxel—ovarian cancer	0.000128	0.000542	CcSEcCtD
Nefazodone—Body temperature increased—Docetaxel—ovarian cancer	0.000128	0.000542	CcSEcCtD
Nefazodone—CYP3A4—female reproductive system—ovarian cancer	0.000128	0.0147	CbGeAlD
Nefazodone—Chills—Doxorubicin—ovarian cancer	0.000128	0.00054	CcSEcCtD
Nefazodone—Dizziness—Paclitaxel—ovarian cancer	0.000126	0.000535	CcSEcCtD
Nefazodone—Vision blurred—Epirubicin—ovarian cancer	0.000126	0.000534	CcSEcCtD
Nefazodone—CYP2D6—female reproductive system—ovarian cancer	0.000126	0.0145	CbGeAlD
Nefazodone—Alopecia—Doxorubicin—ovarian cancer	0.000126	0.000532	CcSEcCtD
Nefazodone—HTR2A—vagina—ovarian cancer	0.000125	0.0144	CbGeAlD
Nefazodone—Ill-defined disorder—Epirubicin—ovarian cancer	0.000124	0.000526	CcSEcCtD
Nefazodone—Anaemia—Epirubicin—ovarian cancer	0.000124	0.000524	CcSEcCtD
Nefazodone—Agitation—Epirubicin—ovarian cancer	0.000123	0.000521	CcSEcCtD
Nefazodone—Flatulence—Doxorubicin—ovarian cancer	0.000122	0.000517	CcSEcCtD
Nefazodone—ABCB1—epithelium—ovarian cancer	0.000122	0.014	CbGeAlD
Nefazodone—Vomiting—Paclitaxel—ovarian cancer	0.000121	0.000514	CcSEcCtD
Nefazodone—Dysgeusia—Doxorubicin—ovarian cancer	0.000121	0.000513	CcSEcCtD
Nefazodone—ABCB1—uterine cervix—ovarian cancer	0.000121	0.0139	CbGeAlD
Nefazodone—Malaise—Epirubicin—ovarian cancer	0.000121	0.000511	CcSEcCtD
Nefazodone—Rash—Paclitaxel—ovarian cancer	0.00012	0.00051	CcSEcCtD
Nefazodone—Dermatitis—Paclitaxel—ovarian cancer	0.00012	0.00051	CcSEcCtD
Nefazodone—Vertigo—Epirubicin—ovarian cancer	0.00012	0.000509	CcSEcCtD
Nefazodone—Syncope—Epirubicin—ovarian cancer	0.00012	0.000508	CcSEcCtD
Nefazodone—Leukopenia—Epirubicin—ovarian cancer	0.00012	0.000507	CcSEcCtD
Nefazodone—Back pain—Doxorubicin—ovarian cancer	0.00012	0.000507	CcSEcCtD
Nefazodone—Headache—Paclitaxel—ovarian cancer	0.00012	0.000507	CcSEcCtD
Nefazodone—Hypersensitivity—Docetaxel—ovarian cancer	0.000119	0.000505	CcSEcCtD
Nefazodone—Muscle spasms—Doxorubicin—ovarian cancer	0.000119	0.000504	CcSEcCtD
Nefazodone—Palpitations—Epirubicin—ovarian cancer	0.000118	0.000501	CcSEcCtD
Nefazodone—Loss of consciousness—Epirubicin—ovarian cancer	0.000118	0.000498	CcSEcCtD
Nefazodone—Cough—Epirubicin—ovarian cancer	0.000117	0.000494	CcSEcCtD
Nefazodone—Vision blurred—Doxorubicin—ovarian cancer	0.000117	0.000494	CcSEcCtD
Nefazodone—Asthenia—Docetaxel—ovarian cancer	0.000116	0.000492	CcSEcCtD
Nefazodone—Convulsion—Epirubicin—ovarian cancer	0.000116	0.000491	CcSEcCtD
Nefazodone—Hypertension—Epirubicin—ovarian cancer	0.000115	0.000489	CcSEcCtD
Nefazodone—ABCB1—decidua—ovarian cancer	0.000115	0.0132	CbGeAlD
Nefazodone—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000115	0.000486	CcSEcCtD
Nefazodone—Domperidone—ABCB1—ovarian cancer	0.000115	0.241	CrCbGaD
Nefazodone—Pruritus—Docetaxel—ovarian cancer	0.000115	0.000485	CcSEcCtD
Nefazodone—Anaemia—Doxorubicin—ovarian cancer	0.000114	0.000485	CcSEcCtD
Nefazodone—CYP2D6—female gonad—ovarian cancer	0.000114	0.0132	CbGeAlD
Nefazodone—Arthralgia—Epirubicin—ovarian cancer	0.000114	0.000482	CcSEcCtD
Nefazodone—Chest pain—Epirubicin—ovarian cancer	0.000114	0.000482	CcSEcCtD
Nefazodone—Myalgia—Epirubicin—ovarian cancer	0.000114	0.000482	CcSEcCtD
Nefazodone—Agitation—Doxorubicin—ovarian cancer	0.000114	0.000482	CcSEcCtD
Nefazodone—Anxiety—Epirubicin—ovarian cancer	0.000113	0.000481	CcSEcCtD
Nefazodone—Nausea—Paclitaxel—ovarian cancer	0.000113	0.00048	CcSEcCtD
Nefazodone—Discomfort—Epirubicin—ovarian cancer	0.000113	0.000477	CcSEcCtD
Nefazodone—Malaise—Doxorubicin—ovarian cancer	0.000112	0.000473	CcSEcCtD
Nefazodone—Dry mouth—Epirubicin—ovarian cancer	0.000111	0.000472	CcSEcCtD
Nefazodone—HTR2A—testis—ovarian cancer	0.000111	0.0128	CbGeAlD
Nefazodone—Vertigo—Doxorubicin—ovarian cancer	0.000111	0.000471	CcSEcCtD
Nefazodone—Syncope—Doxorubicin—ovarian cancer	0.000111	0.00047	CcSEcCtD
Nefazodone—Leukopenia—Doxorubicin—ovarian cancer	0.000111	0.000469	CcSEcCtD
Nefazodone—Diarrhoea—Docetaxel—ovarian cancer	0.000111	0.000469	CcSEcCtD
Nefazodone—Confusional state—Epirubicin—ovarian cancer	0.00011	0.000466	CcSEcCtD
Nefazodone—Palpitations—Doxorubicin—ovarian cancer	0.000109	0.000463	CcSEcCtD
Nefazodone—Oedema—Epirubicin—ovarian cancer	0.000109	0.000462	CcSEcCtD
Nefazodone—Anaphylactic shock—Epirubicin—ovarian cancer	0.000109	0.000462	CcSEcCtD
Nefazodone—ABCB1—endometrium—ovarian cancer	0.000109	0.0126	CbGeAlD
Nefazodone—Loss of consciousness—Doxorubicin—ovarian cancer	0.000109	0.000461	CcSEcCtD
Nefazodone—Infection—Epirubicin—ovarian cancer	0.000108	0.000459	CcSEcCtD
Nefazodone—Cough—Doxorubicin—ovarian cancer	0.000108	0.000457	CcSEcCtD
Nefazodone—Shock—Epirubicin—ovarian cancer	0.000107	0.000455	CcSEcCtD
Nefazodone—Convulsion—Doxorubicin—ovarian cancer	0.000107	0.000454	CcSEcCtD
Nefazodone—Dizziness—Docetaxel—ovarian cancer	0.000107	0.000453	CcSEcCtD
Nefazodone—Thrombocytopenia—Epirubicin—ovarian cancer	0.000107	0.000453	CcSEcCtD
Nefazodone—Hypertension—Doxorubicin—ovarian cancer	0.000107	0.000453	CcSEcCtD
Nefazodone—Tachycardia—Epirubicin—ovarian cancer	0.000107	0.000451	CcSEcCtD
Nefazodone—Hyperhidrosis—Epirubicin—ovarian cancer	0.000106	0.000447	CcSEcCtD
Nefazodone—Myalgia—Doxorubicin—ovarian cancer	0.000105	0.000446	CcSEcCtD
Nefazodone—Arthralgia—Doxorubicin—ovarian cancer	0.000105	0.000446	CcSEcCtD
Nefazodone—Chest pain—Doxorubicin—ovarian cancer	0.000105	0.000446	CcSEcCtD
Nefazodone—Anxiety—Doxorubicin—ovarian cancer	0.000105	0.000445	CcSEcCtD
Nefazodone—Discomfort—Doxorubicin—ovarian cancer	0.000104	0.000441	CcSEcCtD
Nefazodone—Anorexia—Epirubicin—ovarian cancer	0.000104	0.000441	CcSEcCtD
Nefazodone—Dry mouth—Doxorubicin—ovarian cancer	0.000103	0.000437	CcSEcCtD
Nefazodone—Vomiting—Docetaxel—ovarian cancer	0.000103	0.000436	CcSEcCtD
Nefazodone—Rash—Docetaxel—ovarian cancer	0.000102	0.000432	CcSEcCtD
Nefazodone—Hypotension—Epirubicin—ovarian cancer	0.000102	0.000432	CcSEcCtD
Nefazodone—Dermatitis—Docetaxel—ovarian cancer	0.000102	0.000432	CcSEcCtD
Nefazodone—Confusional state—Doxorubicin—ovarian cancer	0.000102	0.000431	CcSEcCtD
Nefazodone—CYP2D6—testis—ovarian cancer	0.000101	0.0117	CbGeAlD
Nefazodone—Headache—Docetaxel—ovarian cancer	0.000101	0.000429	CcSEcCtD
Nefazodone—ABCB1—gonad—ovarian cancer	0.000101	0.0117	CbGeAlD
Nefazodone—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000101	0.000428	CcSEcCtD
Nefazodone—Oedema—Doxorubicin—ovarian cancer	0.000101	0.000428	CcSEcCtD
Nefazodone—ABCB1—uterus—ovarian cancer	0.000101	0.0116	CbGeAlD
Nefazodone—Infection—Doxorubicin—ovarian cancer	0.0001	0.000425	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Epirubicin—ovarian cancer	9.95e-05	0.000421	CcSEcCtD
Nefazodone—Shock—Doxorubicin—ovarian cancer	9.94e-05	0.000421	CcSEcCtD
Nefazodone—Thrombocytopenia—Doxorubicin—ovarian cancer	9.89e-05	0.000419	CcSEcCtD
Nefazodone—Insomnia—Epirubicin—ovarian cancer	9.87e-05	0.000418	CcSEcCtD
Nefazodone—Tachycardia—Doxorubicin—ovarian cancer	9.86e-05	0.000418	CcSEcCtD
Nefazodone—Paraesthesia—Epirubicin—ovarian cancer	9.8e-05	0.000415	CcSEcCtD
Nefazodone—Hyperhidrosis—Doxorubicin—ovarian cancer	9.77e-05	0.000414	CcSEcCtD
Nefazodone—Dyspnoea—Epirubicin—ovarian cancer	9.73e-05	0.000412	CcSEcCtD
Nefazodone—Somnolence—Epirubicin—ovarian cancer	9.71e-05	0.000411	CcSEcCtD
Nefazodone—Anorexia—Doxorubicin—ovarian cancer	9.63e-05	0.000408	CcSEcCtD
Nefazodone—Nausea—Docetaxel—ovarian cancer	9.61e-05	0.000407	CcSEcCtD
Nefazodone—Dyspepsia—Epirubicin—ovarian cancer	9.61e-05	0.000407	CcSEcCtD
Nefazodone—ADRA2A—lymph node—ovarian cancer	9.49e-05	0.0109	CbGeAlD
Nefazodone—Decreased appetite—Epirubicin—ovarian cancer	9.49e-05	0.000402	CcSEcCtD
Nefazodone—Hypotension—Doxorubicin—ovarian cancer	9.44e-05	0.0004	CcSEcCtD
Nefazodone—Pain—Epirubicin—ovarian cancer	9.34e-05	0.000395	CcSEcCtD
Nefazodone—Constipation—Epirubicin—ovarian cancer	9.34e-05	0.000395	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	9.2e-05	0.00039	CcSEcCtD
Nefazodone—Insomnia—Doxorubicin—ovarian cancer	9.14e-05	0.000387	CcSEcCtD
Nefazodone—Paraesthesia—Doxorubicin—ovarian cancer	9.07e-05	0.000384	CcSEcCtD
Nefazodone—ABCB1—female reproductive system—ovarian cancer	9.04e-05	0.0104	CbGeAlD
Nefazodone—Dyspnoea—Doxorubicin—ovarian cancer	9.01e-05	0.000381	CcSEcCtD
Nefazodone—Feeling abnormal—Epirubicin—ovarian cancer	9e-05	0.000381	CcSEcCtD
Nefazodone—Somnolence—Doxorubicin—ovarian cancer	8.98e-05	0.00038	CcSEcCtD
Nefazodone—Gastrointestinal pain—Epirubicin—ovarian cancer	8.93e-05	0.000378	CcSEcCtD
Nefazodone—Dyspepsia—Doxorubicin—ovarian cancer	8.89e-05	0.000377	CcSEcCtD
Nefazodone—Aripiprazole—ABCB1—ovarian cancer	8.84e-05	0.186	CrCbGaD
Nefazodone—Trazodone—ABCB1—ovarian cancer	8.8e-05	0.185	CrCbGaD
Nefazodone—Decreased appetite—Doxorubicin—ovarian cancer	8.78e-05	0.000372	CcSEcCtD
Nefazodone—Urticaria—Epirubicin—ovarian cancer	8.67e-05	0.000367	CcSEcCtD
Nefazodone—Pain—Doxorubicin—ovarian cancer	8.64e-05	0.000366	CcSEcCtD
Nefazodone—Constipation—Doxorubicin—ovarian cancer	8.64e-05	0.000366	CcSEcCtD
Nefazodone—Abdominal pain—Epirubicin—ovarian cancer	8.63e-05	0.000366	CcSEcCtD
Nefazodone—Body temperature increased—Epirubicin—ovarian cancer	8.63e-05	0.000366	CcSEcCtD
Nefazodone—ABCB1—bone marrow—ovarian cancer	8.54e-05	0.00984	CbGeAlD
Nefazodone—Feeling abnormal—Doxorubicin—ovarian cancer	8.32e-05	0.000353	CcSEcCtD
Nefazodone—Gastrointestinal pain—Doxorubicin—ovarian cancer	8.26e-05	0.00035	CcSEcCtD
Nefazodone—ABCB1—female gonad—ovarian cancer	8.23e-05	0.00948	CbGeAlD
Nefazodone—ABCB1—vagina—ovarian cancer	8.18e-05	0.00942	CbGeAlD
Nefazodone—Hypersensitivity—Epirubicin—ovarian cancer	8.04e-05	0.000341	CcSEcCtD
Nefazodone—Urticaria—Doxorubicin—ovarian cancer	8.02e-05	0.00034	CcSEcCtD
Nefazodone—Body temperature increased—Doxorubicin—ovarian cancer	7.99e-05	0.000338	CcSEcCtD
Nefazodone—Abdominal pain—Doxorubicin—ovarian cancer	7.99e-05	0.000338	CcSEcCtD
Nefazodone—Asthenia—Epirubicin—ovarian cancer	7.83e-05	0.000332	CcSEcCtD
Nefazodone—Pruritus—Epirubicin—ovarian cancer	7.72e-05	0.000327	CcSEcCtD
Nefazodone—Diarrhoea—Epirubicin—ovarian cancer	7.47e-05	0.000316	CcSEcCtD
Nefazodone—Hypersensitivity—Doxorubicin—ovarian cancer	7.44e-05	0.000315	CcSEcCtD
Nefazodone—ABCB1—testis—ovarian cancer	7.3e-05	0.00841	CbGeAlD
Nefazodone—Asthenia—Doxorubicin—ovarian cancer	7.25e-05	0.000307	CcSEcCtD
Nefazodone—Dizziness—Epirubicin—ovarian cancer	7.22e-05	0.000306	CcSEcCtD
Nefazodone—Pruritus—Doxorubicin—ovarian cancer	7.15e-05	0.000303	CcSEcCtD
Nefazodone—Fluphenazine—ABCB1—ovarian cancer	7.13e-05	0.15	CrCbGaD
Nefazodone—Vomiting—Epirubicin—ovarian cancer	6.94e-05	0.000294	CcSEcCtD
Nefazodone—Diarrhoea—Doxorubicin—ovarian cancer	6.91e-05	0.000293	CcSEcCtD
Nefazodone—Rash—Epirubicin—ovarian cancer	6.88e-05	0.000292	CcSEcCtD
Nefazodone—Dermatitis—Epirubicin—ovarian cancer	6.88e-05	0.000291	CcSEcCtD
Nefazodone—Headache—Epirubicin—ovarian cancer	6.84e-05	0.00029	CcSEcCtD
Nefazodone—Dizziness—Doxorubicin—ovarian cancer	6.68e-05	0.000283	CcSEcCtD
Nefazodone—Nausea—Epirubicin—ovarian cancer	6.48e-05	0.000275	CcSEcCtD
Nefazodone—Vomiting—Doxorubicin—ovarian cancer	6.42e-05	0.000272	CcSEcCtD
Nefazodone—Rash—Doxorubicin—ovarian cancer	6.37e-05	0.00027	CcSEcCtD
Nefazodone—Dermatitis—Doxorubicin—ovarian cancer	6.36e-05	0.00027	CcSEcCtD
Nefazodone—Headache—Doxorubicin—ovarian cancer	6.33e-05	0.000268	CcSEcCtD
Nefazodone—Nausea—Doxorubicin—ovarian cancer	6e-05	0.000254	CcSEcCtD
Nefazodone—Trifluoperazine—ABCB1—ovarian cancer	5.7e-05	0.12	CrCbGaD
Nefazodone—Quetiapine—ABCB1—ovarian cancer	5.53e-05	0.116	CrCbGaD
Nefazodone—ABCB1—lymph node—ovarian cancer	5.29e-05	0.00609	CbGeAlD
Nefazodone—ADRA2A—Signaling Pathways—CAV1—ovarian cancer	3.52e-06	0.000197	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CG—ovarian cancer	3.51e-06	0.000197	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—KRAS—ovarian cancer	3.51e-06	0.000197	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—KRAS—ovarian cancer	3.49e-06	0.000196	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ABCB1—ovarian cancer	3.46e-06	0.000194	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—APC—ovarian cancer	3.45e-06	0.000193	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CG—ovarian cancer	3.45e-06	0.000193	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—NRAS—ovarian cancer	3.45e-06	0.000193	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CD—ovarian cancer	3.41e-06	0.000191	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—TYMS—ovarian cancer	3.4e-06	0.000191	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ESR1—ovarian cancer	3.39e-06	0.00019	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—PIK3CA—ovarian cancer	3.38e-06	0.00019	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—MAPK3—ovarian cancer	3.37e-06	0.000189	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CD—ovarian cancer	3.37e-06	0.000189	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—KRAS—ovarian cancer	3.34e-06	0.000187	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6ST—ovarian cancer	3.33e-06	0.000187	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—MAPK3—ovarian cancer	3.3e-06	0.000185	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—PIK3CA—ovarian cancer	3.22e-06	0.000181	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTEN—ovarian cancer	3.21e-06	0.00018	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—MAPK1—ovarian cancer	3.21e-06	0.00018	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—EGFR—ovarian cancer	3.21e-06	0.00018	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—PIK3CA—ovarian cancer	3.2e-06	0.00018	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CG—ovarian cancer	3.2e-06	0.00018	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APC—ovarian cancer	3.2e-06	0.00018	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—NRAS—ovarian cancer	3.2e-06	0.00018	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ERBB2—ovarian cancer	3.16e-06	0.000178	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ERBB2—ovarian cancer	3.15e-06	0.000177	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—MAPK1—ovarian cancer	3.14e-06	0.000176	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—EGFR—ovarian cancer	3.14e-06	0.000176	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MTOR—ovarian cancer	3.12e-06	0.000175	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CB—ovarian cancer	3.12e-06	0.000175	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CB—ovarian cancer	3.11e-06	0.000174	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MTOR—ovarian cancer	3.11e-06	0.000174	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CD—ovarian cancer	3.09e-06	0.000174	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CD—ovarian cancer	3.08e-06	0.000173	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—PIK3CA—ovarian cancer	3.07e-06	0.000172	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—MAPK3—ovarian cancer	3.07e-06	0.000172	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—PIK3CA—ovarian cancer	3.06e-06	0.000172	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CD—ovarian cancer	3.03e-06	0.00017	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—KRAS—ovarian cancer	3.03e-06	0.00017	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—FASN—ovarian cancer	3.02e-06	0.000169	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ERBB2—ovarian cancer	3.01e-06	0.000169	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—PIK3CA—ovarian cancer	3e-06	0.000168	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCL8—ovarian cancer	3e-06	0.000168	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCL8—ovarian cancer	2.98e-06	0.000167	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—HRAS—ovarian cancer	2.98e-06	0.000167	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CB—ovarian cancer	2.97e-06	0.000167	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MTOR—ovarian cancer	2.97e-06	0.000167	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC5A5—ovarian cancer	2.97e-06	0.000167	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—KRAS—ovarian cancer	2.97e-06	0.000166	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—HRAS—ovarian cancer	2.96e-06	0.000166	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CB—ovarian cancer	2.93e-06	0.000165	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CDKN1B—ovarian cancer	2.93e-06	0.000164	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—MAPK1—ovarian cancer	2.92e-06	0.000164	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—EGFR—ovarian cancer	2.92e-06	0.000164	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CDKN1B—ovarian cancer	2.91e-06	0.000164	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CAV1—ovarian cancer	2.91e-06	0.000163	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—AKT1—ovarian cancer	2.9e-06	0.000163	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—AKT1—ovarian cancer	2.88e-06	0.000162	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CASP3—ovarian cancer	2.87e-06	0.000161	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL2—ovarian cancer	2.87e-06	0.000161	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.87e-06	0.000161	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCL8—ovarian cancer	2.86e-06	0.00016	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CASP3—ovarian cancer	2.86e-06	0.00016	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6—ovarian cancer	2.85e-06	0.00016	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL2—ovarian cancer	2.85e-06	0.00016	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—HRAS—ovarian cancer	2.84e-06	0.000159	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6—ovarian cancer	2.84e-06	0.000159	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CD—ovarian cancer	2.81e-06	0.000158	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCND1—ovarian cancer	2.79e-06	0.000157	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CDKN1B—ovarian cancer	2.79e-06	0.000157	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—PIK3CA—ovarian cancer	2.79e-06	0.000156	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—PIK3CA—ovarian cancer	2.78e-06	0.000156	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCND1—ovarian cancer	2.78e-06	0.000156	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CTNNB1—ovarian cancer	2.77e-06	0.000155	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—AKT1—ovarian cancer	2.76e-06	0.000155	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—KRAS—ovarian cancer	2.76e-06	0.000155	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CTNNB1—ovarian cancer	2.75e-06	0.000155	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.75e-06	0.000154	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CAV1—ovarian cancer	2.74e-06	0.000154	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CASP3—ovarian cancer	2.73e-06	0.000153	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ERBB2—ovarian cancer	2.73e-06	0.000153	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL2—ovarian cancer	2.73e-06	0.000153	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—PIK3CA—ovarian cancer	2.72e-06	0.000153	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6—ovarian cancer	2.72e-06	0.000152	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MMP9—ovarian cancer	2.71e-06	0.000152	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MMP9—ovarian cancer	2.7e-06	0.000151	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PTEN—ovarian cancer	2.7e-06	0.000151	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MTOR—ovarian cancer	2.7e-06	0.000151	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CB—ovarian cancer	2.7e-06	0.000151	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CB—ovarian cancer	2.69e-06	0.000151	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PTEN—ovarian cancer	2.68e-06	0.000151	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ERBB2—ovarian cancer	2.68e-06	0.00015	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCND1—ovarian cancer	2.66e-06	0.000149	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CG—ovarian cancer	2.65e-06	0.000149	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MTOR—ovarian cancer	2.64e-06	0.000148	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CB—ovarian cancer	2.64e-06	0.000148	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CTNNB1—ovarian cancer	2.64e-06	0.000148	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—AKT1—ovarian cancer	2.63e-06	0.000148	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	2.62e-06	0.000147	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCL8—ovarian cancer	2.59e-06	0.000145	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MMP9—ovarian cancer	2.58e-06	0.000145	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	2.57e-06	0.000144	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PTEN—ovarian cancer	2.57e-06	0.000144	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	2.54e-06	0.000142	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTEN—ovarian cancer	2.54e-06	0.000142	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	2.53e-06	0.000142	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	2.53e-06	0.000142	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	2.52e-06	0.000141	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	2.51e-06	0.000141	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	2.5e-06	0.00014	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CG—ovarian cancer	2.5e-06	0.00014	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	2.49e-06	0.00014	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CASP3—ovarian cancer	2.48e-06	0.000139	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	2.48e-06	0.000139	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL2—ovarian cancer	2.48e-06	0.000139	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6—ovarian cancer	2.46e-06	0.000138	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	2.45e-06	0.000138	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	2.45e-06	0.000138	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	2.45e-06	0.000138	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.44e-06	0.000137	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	2.44e-06	0.000137	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	2.43e-06	0.000136	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL2—ovarian cancer	2.42e-06	0.000136	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	2.42e-06	0.000136	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCND1—ovarian cancer	2.41e-06	0.000135	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	2.41e-06	0.000135	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—STAT3—ovarian cancer	2.41e-06	0.000135	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NRAS—ovarian cancer	2.41e-06	0.000135	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—STAT3—ovarian cancer	2.4e-06	0.000135	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NRAS—ovarian cancer	2.39e-06	0.000134	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	2.39e-06	0.000134	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	2.36e-06	0.000133	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	2.36e-06	0.000132	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MMP9—ovarian cancer	2.34e-06	0.000132	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	2.34e-06	0.000131	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	2.34e-06	0.000131	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PTEN—ovarian cancer	2.33e-06	0.000131	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CD—ovarian cancer	2.33e-06	0.000131	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTEN—ovarian cancer	2.32e-06	0.00013	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	2.32e-06	0.00013	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	2.3e-06	0.000129	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	2.3e-06	0.000129	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	2.3e-06	0.000129	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	2.3e-06	0.000129	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	2.29e-06	0.000129	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	2.29e-06	0.000129	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	2.28e-06	0.000128	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	2.28e-06	0.000128	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	2.27e-06	0.000128	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PIK3CA—ovarian cancer	2.27e-06	0.000127	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.26e-06	0.000127	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	2.26e-06	0.000127	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL2—ovarian cancer	2.25e-06	0.000126	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	2.24e-06	0.000126	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MYC—ovarian cancer	2.24e-06	0.000126	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MYC—ovarian cancer	2.23e-06	0.000125	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	2.23e-06	0.000125	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TYMS—ovarian cancer	2.22e-06	0.000125	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	2.2e-06	0.000123	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	2.19e-06	0.000123	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CD—ovarian cancer	2.19e-06	0.000123	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	2.19e-06	0.000123	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EGFR—ovarian cancer	2.19e-06	0.000123	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	2.18e-06	0.000122	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EGFR—ovarian cancer	2.18e-06	0.000122	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	2.18e-06	0.000122	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MYC—ovarian cancer	2.13e-06	0.00012	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	2.13e-06	0.00012	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	2.12e-06	0.000119	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	2.1e-06	0.000118	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	2.09e-06	0.000117	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	2.09e-06	0.000117	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—STAT3—ovarian cancer	2.08e-06	0.000117	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NRAS—ovarian cancer	2.08e-06	0.000117	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KRAS—ovarian cancer	2.07e-06	0.000116	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	2.07e-06	0.000116	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	2.06e-06	0.000116	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KRAS—ovarian cancer	2.06e-06	0.000116	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	2.04e-06	0.000115	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	2.04e-06	0.000114	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CB—ovarian cancer	2.03e-06	0.000114	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	1.99e-06	0.000112	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	1.97e-06	0.000111	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	1.95e-06	0.000109	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MYC—ovarian cancer	1.94e-06	0.000109	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	1.91e-06	0.000107	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.91e-06	0.000107	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	1.9e-06	0.000107	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MYC—ovarian cancer	1.9e-06	0.000106	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	1.9e-06	0.000106	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	1.89e-06	0.000106	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGFR—ovarian cancer	1.89e-06	0.000106	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	1.89e-06	0.000106	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	1.89e-06	0.000106	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	1.85e-06	0.000104	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	1.85e-06	0.000104	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—AKT1—ovarian cancer	1.85e-06	0.000104	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—ovarian cancer	1.84e-06	0.000103	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—ovarian cancer	1.83e-06	0.000103	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	1.81e-06	0.000102	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	1.81e-06	0.000102	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CAV1—ovarian cancer	1.79e-06	0.000101	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KRAS—ovarian cancer	1.79e-06	0.0001	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CA—ovarian cancer	1.79e-06	0.0001	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MYC—ovarian cancer	1.76e-06	9.89e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HRAS—ovarian cancer	1.76e-06	9.88e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTEN—ovarian cancer	1.75e-06	9.84e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—ovarian cancer	1.75e-06	9.84e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	1.75e-06	9.83e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HRAS—ovarian cancer	1.75e-06	9.83e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	1.72e-06	9.67e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	1.72e-06	9.67e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6—ovarian cancer	1.68e-06	9.46e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	1.68e-06	9.41e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6—ovarian cancer	1.68e-06	9.41e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTEN—ovarian cancer	1.65e-06	9.27e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	1.64e-06	9.23e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CA—ovarian cancer	1.64e-06	9.2e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.63e-06	9.16e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	1.63e-06	9.14e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	1.61e-06	9.03e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6—ovarian cancer	1.6e-06	9.01e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—ovarian cancer	1.59e-06	8.93e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—ovarian cancer	1.56e-06	8.74e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AKT1—ovarian cancer	1.55e-06	8.72e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AKT1—ovarian cancer	1.55e-06	8.68e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HRAS—ovarian cancer	1.52e-06	8.54e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	1.5e-06	8.39e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	1.49e-06	8.36e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	1.48e-06	8.31e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—AKT1—ovarian cancer	1.46e-06	8.2e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6—ovarian cancer	1.46e-06	8.17e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—ovarian cancer	1.45e-06	8.12e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.43e-06	8.05e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6—ovarian cancer	1.43e-06	8e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	1.38e-06	7.77e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AKT1—ovarian cancer	1.34e-06	7.54e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—AKT1—ovarian cancer	1.34e-06	7.51e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6—ovarian cancer	1.32e-06	7.43e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	1.31e-06	7.38e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.25e-06	7.02e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.24e-06	6.94e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	1.22e-06	6.86e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.17e-06	6.54e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTEN—ovarian cancer	1.08e-06	6.06e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AKT1—ovarian cancer	1.01e-06	5.67e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AKT1—ovarian cancer	9.52e-07	5.34e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CA—ovarian cancer	7.62e-07	4.28e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AKT1—ovarian cancer	6.22e-07	3.49e-05	CbGpPWpGaD
